Nivolumab inhibits programmed cell-death protein-1 (PD-1)–mediated signaling by blocking its ligand (PD-L1])from binding to it [3], thereby preventing reactivation of cytotoxic activity [4] and expansion of clonal T cells recognizing tumor-specific antigens [5]. This evidence concerns the gene PDCD1 and neoplasm.